San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 6.3% in the afternoon session after the company, in partnership with GSK, announced a major update to its Vaccine Track data tool for tracking adult immunization activity in the U.S. The enhancement adds local-level data for 387 metro areas and expands the dataset to a full decade of information. This update is designed to help public health organizations and providers identify immunization gaps and improve their community outreach efforts. The collaboration with pharmaceutical giant GSK underscores IQVIA's role in providing critical health data analytics. This development occurs within a positive industry context, as the broader biologics contract research organization market, a key sector for IQVIA, is projected to experience strong growth due to increased outsourcing of R&D by large pharmaceutical firms.
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year trend of muted returns for a sector traditionally viewed as defensive and resilient. The underperformance is not merely
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 2.3% in the afternoon session after the company announced the launch of a new AI-powered platform to manage the financial aspects of clinical trials.
Firefly Neuroscience (AIFF) stock up after unveiling CLEAR Platform powered by Nvidia's (NVDA) L40S GPU for improved EEG data quality and processing speed.
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospect of lower borrowing costs bolstered investor confidence, particularly in sectors that have lagged, leading to a broad rally across the market.
A number of stocks fell in the morning session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q2, starting with IQVIA (NYSE:IQV).
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 3% in the afternoon session on continued positive momentum after the company reported better-than-expected second-quarter earnings and received several price target increases from Wall Street analysts.
Clinical research company IQVIA (NYSE: IQV) announced better-than-expected revenue in Q2 CY2025, with sales up 5.3% year on year to $4.02 billion. The company’s full-year revenue guidance of $16.2 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $2.81 per share was 1.4% above analysts’ consensus estimates.
